Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test |
| |
Authors: | JP Redrobe and M. Bourin |
| |
Affiliation: | GIS Medicament, JE 2027 Neurobiologie de l'Anxieté, Facultéde Médecine BP 53508, I rue Gaston Veil, 44035 Nantes cedex 01, France |
| |
Abstract: | Summary— The aim of the present study was the investigation of pretreatment effects with clonidine (0.06 mg/kg, intraperitoneal [ip]), lithium (1 mEq, ip) or quinine (0.5 mg/kg, ip) on the activities of various drugs acting on noradrenergic and/or serotonergic systems in the mouse tail suspension test. Drugs used in the present study included: the tricyclic antidepressants imipramine and dothiepin, the heterocyclic antidepressant trazodone, the 5-HT reuptake inhibitor (SSRI) fluoxetine, the atypical antidepressants mianserin and iprindole, the 5-HT1A receptor agonist ipsapirone, the 5-HT2A/2C receptor antagonist ritanserin, and the 5-HT3 receptor antagonist ondansetron. Clonidine, lithium and quinine differentially enhanced the effects of several psychotropic drugs administered at sub-active doses. The activity of iprindole (32 mg/kg, ip) was not potentiated by pretreatment with clonidine, lithium or quinine. Our results suggest that lithium exerted additive effects via postsynaptic 5-HT1A receptor activation, quinine via potassium ion channel blockade of 5-HT3 receptors, while clonidine did so primarily via action at 5-HT2 receptors. |
| |
Keywords: | lithium clonidine quinine antidepressant tail suspension test |
|
|